What Side Effects May Be Caused by Capmatinib?

Common side effects include fluid retention, nausea, vomiting, myalgia, fatigue, and asthenia.

What Side Effects May Be Caused by Capmatinib?

In addition to its intended effects, a medication may cause some unwanted side effects. Although not all these side effects may occur, if they do, medical attention may be necessary.

Contact your doctor immediately if you experience any of the following side effects:

Common symptoms include swelling of the face, arms, hands, lower legs, or feet; chest pain or tightness; chills; clay-colored stools; cough; dark urine; decreased or loss of appetite; difficulty breathing; fever; general malaise; headache; pruritus; nausea and vomiting; rapid weight gain; skin rash; stomach pain or tenderness; swelling of the feet or lower legs; increased bronchial secretions; tingling sensation in the hands and feet; abnormal weight gain or loss; unusual tiredness or weakness; as well as yellowing of the eyes or skin.

How to Dispose of Unneeded or Expired Capmatinib

Take the medication to a drug take-back point for disposal. You may consult your pharmacy or law enforcement agency to find a take-back location nearby.

If you cannot return the medication, check the label or package insert to determine whether it should be discarded in household trash or flushed down the toilet. If you are unsure, consult your healthcare team. If it is safe to discard in trash, remove the medication from its container, mix it with cat litter, dirt, coffee grounds, or other waste materials, then seal it in a bag or container before throwing it into the garbage bin.

Precautions for Capmatinib

1. Interstitial Lung Disease (ILD)/Pneumonitis: Fatal cases of ILD/pneumonitis have been reported in clinical trials. Monitor for new or worsening pulmonary symptoms that may indicate ILD/pneumonitis.

2. Hepatotoxicity: Hepatotoxicity has been reported. Conduct liver function tests (including alanine aminotransferase [ALT], aspartate aminotransferase [AST], and total bilirubin) before the start of treatment, every 2 weeks during the first 3 months of treatment, and monthly thereafter or as clinically indicated. Increase the frequency of testing in patients with elevated transaminases or bilirubin.

3. Elevated Amylase and Lipase: Increases in amylase and lipase levels have been observed in treated patients. Monitor amylase and lipase levels at baseline and periodically during treatment. Temporarily interrupt treatment, reduce the dosage, or permanently discontinue treatment based on the severity of adverse reactions.

4. Severe Hypersensitivity Reactions: Severe hypersensitivity reactions have been reported with the use of this product. Signs and symptoms of hypersensitivity reactions include fever, chills, pruritus, skin rash, hypotension, nausea, and vomiting. Temporarily interrupt treatment or permanently discontinue treatment based on the severity of adverse reactions.

5. Possible Photosensitivity Reaction: Advise patients to limit direct exposure to ultraviolet (UV) light. Minimize direct UV exposure by using sunscreen or protective clothing during treatment.

6. Potential Fetal Harm: This drug may cause fetal harm.